ライフサイエンスコーパス: clinical testing

1 inical model, establishing the rationale for clinical testing.

2 should have significant influence on future clinical testing.

3 re identified in research projects or during clinical testing.

4 atients with CKD are available and ready for clinical testing.

5 pproved in 2006 and 2009 following extensive clinical testing.

6 sion that can be gradually incorporated into clinical testing.

7 to prevent relapse are in various phases of clinical testing.

8 ll-molecule inhibitors are reported to be in clinical testing.

9 ersion from MCI to AD compared with baseline clinical testing.

10 clinical management of patients referred for clinical testing.

11 mising polymer-drug conjugate progressing to clinical testing.

12 hies, and that EpoD could be a candidate for clinical testing.

13 slational approach including preclinical and clinical testing.

14 ographic atrophy in both pre and early-phase clinical testing.

15 muli that contained no monocular cues and on clinical testing.

16 a specific kinase inhibitor already in human clinical testing.

17 nt CLL patients would improve outcome merits clinical testing.

18 e activity that is in phase II and phase III clinical testing.

19 utcomes and may not optimally translate into clinical testing.

20 th neurodevelopmental disorders referred for clinical testing.

21 latory therapy tools available for immediate clinical testing.

22 ibitor compound, MP-10, has recently entered clinical testing.

23 bitors uncovered in this study are ready for clinical testing.

24 sults to frozen samples for multiple-analyte clinical testing.

25 g/kg every 3 months was selected for further clinical testing.

26 e bench into developmental programmes before clinical testing.

27 n-derived Abs promising candidates for human clinical testing.

28 es that block this integrin are currently in clinical testing.

29 e, and test interval are needed for reliable clinical testing.

30 e tested in assays that are more amenable to clinical testing.

31 , preclinical proof of concept, and possible clinical testing.

32 c treatment of cancer in humans and warrants clinical testing.

33 make this chemoimmunotherapy attractive for clinical testing.

34 approaches are undergoing further randomized clinical testing.

35 sently, at least two drugs are in late-stage clinical testing.

36 al-based emulsions are in advanced stages of clinical testing.

37 n of T. vaginalis PCR diagnosis into routine clinical testing.

38 eir efficacy against malaria awaits rigorous clinical testing.

39 otherapeutic strategy may be appropriate for clinical testing.

40 h inhibitory agents are currently undergoing clinical testing.

41 ese devices into the field for point-of-care clinical testing.

42 be addressed as these agents undergo further clinical testing.

43 easures by which they may be prioritized for clinical testing.

44 crotubule-targeting compounds are undergoing clinical testing.

45 ntal strategies currently in preclinical and clinical testing.

46 ve culminated in vaccine candidates entering clinical testing.

47 select which form of an antigen to take into clinical testing.

48 ng more potent cancer vaccine strategies for clinical testing.

49 mphomas and warrants further preclinical and clinical testing.

50 readily identified and are more amenable to clinical testing.

51 anti-angiogenic agents and are currently in clinical testing.

52 is one of the first FT inhibitors to undergo clinical testing.

53 entially in analyzing patient samples during clinical testing.

54 off RT for the assay prior to more extensive clinical testing.

55 e (Porcn) are candidate anticancer agents in clinical testing.

56 ents for diarrhea were identified in routine clinical testing.

57 anufacture, as well as their preclinical and clinical testing.

58 tibody-drug conjugates are now in late-phase clinical testing.

59 genesis of cardiac arrest through systematic clinical testing.

60 esidual diagnostic specimens remaining after clinical testing.

61 nists are being carried forward into phase I clinical testing.

62 genome annotation, comparative genomics, and clinical testing.

63 arly-phase trials only to fail in late-stage clinical testing.

64 new tuberculosis vaccine candidates entering clinical testing.

65 Semaglutide is currently in phase 3 clinical testing.

66 parental virus and merits consideration for clinical testing.

67 Some of these therapies have advanced to clinical testing.

68 but most CDK inhibitors have failed rigorous clinical testing.

69 pplements," which may not require additional clinical testing.

70 the same as vaccines entering Phase 1 human clinical testing.

71 bilization of such protein aggregates are in clinical testing.

72 it convenient for patients to participate in clinical testing.

73 strategy for SCLC treatment, which warrants clinical testing.

74 o minimize it will be important steps before clinical testing.

75 re currently undergoing preclinical or early clinical testing.

76 should be taken forward for experimental or clinical testing.

77 latory drugs that are in the early stages of clinical testing.

78 critical quality attributes appropriate for clinical testing.

79 coding regions of the genome (the exome) for clinical testing.

80 man mHAs in numbers and potency adequate for clinical testing.

81 ied viral pathogens in more samples than did clinical testing (30/90 versus 16/90; McNemar P = 0.001)

82 ts who enrolled prior to the availability of clinical testing, 79 had a 17p12 duplication (CMT1A dupl

83 peutic effects in animal models and in early clinical testing ((90)Y-humanized PAM4 IgG, (90)Y-clivat

84 In clinical testing, Abs against PD-1 have resulted in psor

85 and support their further development toward clinical testing against cervical intraepithelial neopla

86 of predicting conversion to AD compared with clinical testing alone.

87 These results indicate that BEZ235 merits clinical testing, alone and in combination with other ag

88 e respiratory samples obtained after routine clinical testing and 27 matched liquid cultures).

89 ration of HER2-targeting agents brought into clinical testing and a renewed attempt to treat HER2-dri

90 ber of these approaches have entered initial clinical testing and already provide intriguing new info

91 we review the studies that brought MPIs into clinical testing and discuss the design and outcome of t

92 cific antigen combinations for high-priority clinical testing and establishes a generalizable approac

93 n-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement

94 Although RTS,S has undergone extensive clinical testing and has progressed through phase III cl

95 decay engineering to design new formats for clinical testing and other fluorescence-based applicatio

96 accuracies in wavefront error may compromise clinical testing and refractive correction procedures.

97 cardiac arrest patients requires systematic clinical testing and regular follow-up to unmask the cau

98 Hence, there is a critical interplay between clinical testing and research leading to gene-disease as

99 Appropriate clinical testing and risk stratification are essential t

100 mportance of assessing a temporal window for clinical testing and thereby questioning the accuracy of

101 The development of biomarkers for clinical testing and validation can be facilitated by th

102 All had a myopathy by clinical evaluation, clinical testing, and biopsy.

103 s (JTT-705 and torcetrapib) are currently in clinical testing, and significantly raise high-density l

104 Several bnMAbs are currently in clinical testing, and we offer perspectives on their use

105 al mutant FLT3 inhibitors that is undergoing clinical testing, and which is currently in late-stage c

106 effective non-toxic doses for more extensive clinical testing; and to establish a relationship betwee

107 ghted and future directions for research and clinical testing are discussed.

108 tions of these results in vaccine design and clinical testing are discussed.

109 Advances in diagnostic clinical testing are reviewed, including updates on angi

110 he cell surface receptor cKit are undergoing clinical testing as a cell source for heart failure and

111 se activity, is currently undergoing Phase I clinical testing as a potential antineoplastic agent.

112 G and IC/anti-CTLA-4 should be developed for clinical testing as a potentially effective novel immuno

113 ies of functional scFvSA can be produced for clinical testing as a therapy for non-Hodgkin's lymphoma

114 nase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.

115 NA should be further developed for potential clinical testing as an approach for human cancer gene th

116 arious stages of preclinical and early phase clinical testing as potential anticancer drugs.

117 anner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically

118 ents of T-tau and P-tau performed in routine clinical testing at the Clinical Neurochemistry Laborato

119 cology failures reached expensive late-stage clinical testing before being abandoned.

120 Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many h

121 rimarily related to lack of easily available clinical testing, but other factors included the presenc

122 80,633, based on its inhibitory potency, for clinical testing by topical, bilateral paired comparison

123 In situations in which clinical testing cannot be performed or when uncertainty

124 A clinical testing cohort was used to gain a broader under

125 Under typical clinical testing conditions, increased forward scatter h

126 ective tool for verification of C. difficile clinical testing criteria and safe reduction of inflated

127 ighlight the importance of using appropriate clinical testing criteria.

128 ent de novo events were further evaluated in clinical-testing data from Children's Hospital Boston an

129 We assessed clinical testing dates, approved indications, and regula

130 r locations designed to match those found in clinical testing environments.

131 Unexpected drug activities discovered during clinical testing establish the need for better character

132 oriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders

133 tumorigenesis, and Notch antagonists are in clinical testing for application in cancer.

134 Clinical testing for BMPR2 mutations is available and ma

135 ardial infarction and are undergoing further clinical testing for cardiomyopathy.

136 potent CCR5 coreceptor antagonist that is in clinical testing for daily oral pre-exposure prophylaxis

137 ults with cirrhosis, suggesting that further clinical testing for HE is warranted.

138 reatments that are undergoing preclinical or clinical testing for hypertension treatment.

139 rationale for extending HDAC inhibitors into clinical testing for indications involving these organs.

140 ation approaches likely to move forward into clinical testing for lymphomas.

141 notherapies currently in worldwide phase III clinical testing for melanoma are discussed.

142 receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently

143 f adefovir (PMEA), is currently in phase III clinical testing for the treatment of human immunodefici

144 I-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours

145 Routine clinical testing for these specific mutations is of low

146 half-life, are also important factors in the clinical testing for this virus.

147 targeting this protein that are amenable for clinical testing has been challenging.

148 Pre-clinical testing has contributed to the recent approval

149 Early prototype development and clinical testing have shown that a consumer digital came

150 Successes in randomized clinical testing have supported the growing appreciation

151 less likely to fail in the various stages of clinical testing, have fewer postapproval withdrawals, a

152 otoxin A), showed limited promise in initial clinical testing, highlighting the need for improved ITs

153 liable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a s

154 l biases are generally not considered during clinical testing; however, we suggest that such biases m

155 tide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies.

156 enough in human beings to allow large-scale clinical testing in healthy people.

157 ent sensitivity and specificity suitable for clinical testing in high-risk populations.

158 t CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies.

159 and generates proof-of-concept for ARGX-111 clinical testing in MET-positive oncologic malignancies.

160 nst the VEGF receptor have undergone initial clinical testing in metastatic RCC with substantial obje

161 inical models provided the framework for its clinical testing in MM, which has already provided favor

162 he need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously tran

163 erated c-Met inhibitor, currently in Phase 3 clinical testing in non-small cell lung cancer patients.

164 reating metastatic TNBC and warrants further clinical testing in patients.

165 very, early drug development, and definitive clinical testing in pivotal trials.

166 findings offer a rational strategy to guide clinical testing in preidentified subsets of patients wh

167 This opens the possibility of clinical testing in rheumatic diseases of childhood.

168 ntly, several VEGF inhibitors are undergoing clinical testing in several malignancies.

169 stigational compound is currently in phase 1 clinical testing in subjects with hemophilia A or B.

170 to replace conventional long and costly pre-clinical testing in the new drug administration process.

171 ly focused approaches for gene discovery and clinical testing in the next few years.

172 een substantiated with their development and clinical testing in the treatment of cancer.

173 -inducing potential are currently undergoing clinical testing in transplantation, autoimmune diseases

174 re currently under intensive development and clinical testing) in individuals with DN and perhaps oth

175 into the assay process during the period of clinical testing included software enhancements, improve

176 Clinical testing included visual acuity, visual fields,

177 scue was evaluated using non-invasive, human clinical testing, including fundus auto-fluorescence, op

178 al, a variety of anti-HIV genes have reached clinical testing, including gene-editing enzymes, protei

179 and currently at least 33 different drugs in clinical testing--including several in pivotal trials--c

180 Preclinical and early phase I clinical testing indicates that effective concentrations

181 (bsAbs) on a large scale for preclinical and clinical testing is a challenging task.

182 ever received a BRAF inhibitor; confirmatory clinical testing is ongoing.

183 g MRR based malaria diagnostics suitable for clinical testing is the fact that MRR baseline fluctuati

184 However, in clinical testing, it has shown limited benefit in patien

185 Interpretations are submitted by clinical testing laboratories, research laboratories, lo

186 ques, and extensive bench, pre-clinical, and clinical testing, lead failure (LF) remains the Achilles

187 ion discrepancies between patient report and clinical testing may be owing to home lighting may initi

188 of mutations in this disease, the results of clinical testing of 699 advanced melanoma patients using

189 Clinical testing of a human IgG1 anti-CD27 Ab, varliluma

190 e forms of several therapeutic proteins, and clinical testing of a monthly formulation human growth h

191 rovides a brief outline of the plans for the clinical testing of a multistage, multiantigen malaria v

192 we demonstrate the technical development and clinical testing of a novel electronics enabled microflu

193 ility genes at once, suggesting that routine clinical testing of all incidence cases should be consid

194 th melanoma providing a strong rationale for clinical testing of alternative dosing regimens.

195 Results provide a rationale for broader clinical testing of AT1R-targeted molecular imaging.

196 to the identification, characterization, and clinical testing of ataluren, a new therapeutic with the

197 normal caspase-1 activation, and support the clinical testing of caspase-1 inhibitors such as VX-765

198 This study suggests that clinical testing of celecoxib as a preventive for hepati

199 Clinical testing of CEP-701 as a novel molecularly targe

200 tion and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted th

201 efficacious in these models, indicating that clinical testing of combinations of BCR-ABL kinase inhib

202 Our findings strongly support the clinical testing of combined hormone antagonist-low-leve

203 Further clinical testing of DENVax in different age groups and i

204 We initiated clinical testing of engineered T cells expressing an aff

205 provide rationale and practical platform for clinical testing of expanded and activated NK cells for

206 Clinical testing of FLT3 inhibitors as molecularly targe

207 acute lymphoblastic leukemia (T-ALL) led to clinical testing of gamma-secretase inhibitors (GSIs) th

208 hese results provide compelling evidence for clinical testing of IMiDs alone and in combination with

209 uced at higher temperatures enabling on-site clinical testing of infectious agents.

210 Phase I clinical testing of inhibition of Janus kinase 2, active

211 tial as a non-human animal model for the pre-clinical testing of iNKT-stimulating glycolipids.

212 These data provide a rationale for clinical testing of intracoronary bFGF in ischemic heart

213 enhanced activity and to support the future clinical testing of intratumoral administration of immun

214 st time in humans, we carried out a Phase II clinical testing of intratumoral and peritumoral ONYX-01

215 In summary, our results support the clinical testing of lymphodepletion and PD-1/PD-L1 block

216 These results warrant further clinical testing of META060 for its therapeutic potentia

217 tients with acute diarrhea have included the clinical testing of modifications to the standard oral r

218 antitumor activity of ANAs might support the clinical testing of monoclonal ANAs as a cancer therapy,

219 tability measurements have been proposed for clinical testing of nerve function, since excitability m

220 he feasibility for using challenge models in clinical testing of new disease intervention strategies.

221 Pharmaceutical research requires pre-clinical testing of new therapeutics using both in-vitro

222 design, and a mechanistic rationale for the clinical testing of nonviral miRNA mimetics.

223 with conventional screening and monotherapy clinical testing of novel agents.

224 ertaken into the development and preliminary clinical testing of novel technologies including robotic

225 ental model also shows merit for early phase clinical testing of novel therapeutic agents.

226 It set the stage for clinical testing of novel therapeutic strategies, such a

227 ce and risk, consideration might be given to clinical testing of PALB2 by complete genomic sequencing

228 These experiments support the clinical testing of pDNA vaccine candidates that may ult

229 e findings may support the rationale for the clinical testing of peripherally restricted CB1R antagon

230 hat has implications for the development and clinical testing of PI3K pathway inhibitors.

231 Our findings support the clinical testing of PKC412 for treatment of mutant PDGFR

232 t important and most difficult criteria, the clinical testing of potent and selective ET receptor ant

233 nt method for high-content screening and pre-clinical testing of potential STAT3 inhibitors in live c

234 ity of PR-171 and provide validation for the clinical testing of PR-171 in the treatment of hematolog

235 This assay/system performed well in clinical testing of regular seasonal influenza virus sub

236 The clinical testing of rotavirus vaccines from early safety

237 This study establishes a foundation for clinical testing of sequential fractionated radiation fo

238 d in this study provides a rationale for the clinical testing of SGN-40 in the treatment of CD40+ B-l

239 ation and provide a strong rationale for the clinical testing of TGF-beta signaling blockade to enhan

240 Based on these findings, clinical testing of the BIBW2992/rapamycin combination i

241 based on laboratory hypotheses, but without clinical testing of the hypotheses to show utility for t

242 rant further development and preclinical and clinical testing of the next generation of candidate MAP

243 provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762

244 e present work describes the development and clinical testing of the paper-based biosensor that measu

245 pments lie mostly in the lessons learnt from clinical testing of these approaches.

246 vivo, thus providing a strong rationale for clinical testing of this agent in patients with ALL.

247 These results therefore support clinical testing of this noninvasive-targeted drug deliv

248 CD33-directed antitumor activity and support clinical testing of this novel therapeutic in patients w

249 regulators and provides a rational basis for clinical testing of this therapeutic approach.

250 uses and temozolomide, and should propel the clinical testing of this therapy approach in patients wi

251 These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM.

252 otential of more pragmatic approaches to the clinical testing of vaccine candidates, the field has pr

253 targeting of CSC prompts a new paradigm for clinical testing of VS-5584: clinical trials designed wi

254 arrying a SPRED1 mutation identified through clinical testing participated with their families in a g

255 s injection methods for use in such areas as clinical testing, pharmaceutical analysis, and environme

256 er of drug candidates and accelerate the pre-clinical testing process subject to animal testing upon

257 stimation of CA activity in erythrocytes for clinical testing purposes.

258 -2-family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

259 -2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

260 Clinical testing reliability was compared between expert

261 iants in genes associated with CPVT from WES clinical testing represent disease-associated biomarkers

262 However, clinical testing revealed a high incidence of duplicatio

263 tion of 120 sequential samples submitted for clinical testing revealed a variety of silent and amino

264 Clinical testing revealed ipsilateral postoperative incr

265 ned from finger prick (Theranos) and 2 major clinical testing services that require standard venipunc

266 Clinical testing showed 95% sensitivity for influenza A

267 n significant cost savings when applied to a clinical testing strategy.

268 When instructed as for clinical testing, subjects respond to the presence of th

269 Early clinical testing suggests that eplerenone may have impor

270 Results from transgenic mice and extensive clinical testing support the hypothesis that biallelic B

271 as testified by the number of candidates in clinical testing that unselectively target both PARP-1 a

272 eutics have been approved or are in advanced clinical testing, the development of more sophisticated

273 elf, experimental medicine, and larger-scale clinical testing-there are specific needs for academic p

274 Because DOTATOC has undergone extensive clinical testing, this human reporter system has the pot

275 ugh ethyl pyruvate has undergone early-phase clinical testing, this was done without consideration of

276 ure for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasi

277 development strategies and outcomes of their clinical testing to date.

278 rate reactions in the same assay for routine clinical testing to detect influenza A and B viruses and

279 ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia

280 man study groups and is now undergoing wider clinical testing to secure FDA approval for general use.

281 compounds transition from discovery, through clinical testing, to drugs.

282 mising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations

283 positive negative controls in HP and CAP/CTM clinical testing was <0.5% over 6 to 7 months of testing

284 nce of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring

285 tatic uveal melanoma did not warrant further clinical testing when assessed by ORR, although minor tu

286 models, extended safety studies and further clinical testing will be required before the full therap

287 ible loss of visual function in LHON support clinical testing with mutated G11778A mitochondrial DNA

288 ate the advancement of promising projects to clinical testing with the contributions of multidiscipli

289 32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials

290 entific criterion in the field of gingivitis clinical testing would be the independent demonstration